DDrare: Database of Drug Development for Rare Diseases

Searched query = "IgG4-related disease", "Autoimmune pancreatitis", "IgG4-related sclerosing cholangitis", "IgG4-related lacrimal gland, orbital, and salivary gland lesions", "IgG4-related kidney disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 18F-FDG; 68Ga-FAPI; Abatacept; Afucosylated IgG1 kappa monoclonal antibody; Belimumab; Corticosteroids; Device: Mayo Interactive Breath Hold Monitor; Drug free, IS monotherapy and GC combined with IS; Extra blood draw samples; Glucocorticoids; INEBILIZUMAB; Inebilizumab; Leflunomide; Lenalidomide; MONITOR; Methionine; Mycophenolate; Mycophenolate mofetil; Perflubutane; Prednisolone; Prednisone; Prednisone and Belimumab; Prednisone and Mycophenolate mofetil; Procedure: biliary stent; Rilzabrutinib; Rituximab; T 614; Thalidomide; XMAB5871; XmAb5871; Zanubrutinib; Zanubrutinib 80 MG; [XmAb5871]

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03669861 (ClinicalTrials.gov)	November 13, 2018	4/6/2018	Safety and Efficacy of Abatacept in IgG4-Related Disease	A Prospective, Open-label, Single Center Abatacept in IgG4-Related Disease 10-patient Proof-of-concept Study	IgG4-related Disease	Drug: Abatacept	Massachusetts General Hospital	Bristol-Myers Squibb	Active, not recruiting	18 Years	N/A	All	10	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03669861
(ClinicalTrials.gov)

November 13, 2018

4/6/2018

Safety and Efficacy of Abatacept in IgG4-Related Disease

A Prospective, Open-label, Single Center Abatacept in IgG4-Related Disease 10-patient Proof-of-concept Study

IgG4-related Disease

Drug: Abatacept

Massachusetts General Hospital

Bristol-Myers Squibb

Active, not recruiting

18 Years

N/A

All

Phase 2

United States